Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
15% lidocaine/5 mg/ml 0.02% estradiol compound cream
(LIDOCAINE PATCH)
2件: Estradiol,
Lidocaine (Maximum Strenght Lidocaine plus Menthol Pain Relief Patch)
3件: Estradiol ,
Lidocaine (LIDOCAINE PATCH),
Lidocaine hydrochloride monohydrate 💬
7件: ESR1,
ESR2,
SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬
13件: Adrenergic signaling in cardiomyocytes, Breast cancer, Chemical carcinogenesis - receptor activation, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway 💬1件: 226 💬
2Alkalinized Lidocaine-Heparin
(LIDOCAINE PATCH)
2件: Heparin,
Lidocaine (Maximum Strenght Lidocaine plus Menthol Pain Relief Patch)
3件: Lidocaine (LIDOCAINE PATCH),
Adomiparin ,
Lidocaine hydrochloride monohydrate 💬
6件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A,
SERPINC1 💬
4件: Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction 💬1件: 226 💬
3All patients in the study will be treated with ocrelizumab1件: Ocrelizumab1件: Ocrelizumab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13 💬
4ALS patients genetic characterization----1件: 2 💬
5ANA001XHCl (Syntagon) or VEXA-04 (Patheon)----1件: 156 💬
6Asthma patients----1件: 299 💬
7Belimumab in SLE patients / Rituximab in RA patients2件: Belimumab,
Rituximab
2件: Rituximab ,
Belimumab 💬
2件: MS4A1,
TNFSF13B 💬
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬2件: 46, 49 💬
8BIIL 284 BS, high dose, adult patients----1件: 299 💬
9BIIL 284 BS, high dose, pediatric patients----1件: 299 💬
10BIIL 284 BS, low dose, adult patients----1件: 299 💬
11BIIL 284 BS, low dose, pediatric patients----1件: 299 💬
12BIIL 284 BS, medium dose, adult patients----1件: 299 💬
13BIIL 284 BS, medium dose, pediatric patients----1件: 299 💬
14Bladder instillation with heparin/ lidocaine
(LIDOCAINE PATCH)
2件: Heparin,
Lidocaine (Maximum Strenght Lidocaine plus Menthol Pain Relief Patch)
3件: Lidocaine (LIDOCAINE PATCH),
Adomiparin ,
Lidocaine hydrochloride monohydrate 💬
6件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A,
SERPINC1 💬
4件: Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction 💬1件: 226 💬
15Buprenorphine Transdermal Patch1件: Buprenorphine1件: Buprenorphine 💬2件: OPRK1,
OPRM1 💬
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬1件: 46 💬
16Capillary colchicine dosage in colchicine-resistant Familial Mediterranean Fever patients.1件: Colchicine1件: Colchicine 💬9件: TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬
10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 266 💬
17Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients----1件: 2 💬
18CF patients with a G551D mutation and treated with Ivacaftor1件: Ivacaftor1件: Ivacaftor 💬1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299 💬
19Cryopreserved EFS-ADA LV transduced patient CD34+ cells----1件: 65 💬
20Cryopreserved G2SCID lentiviral vector transduced patient CD34+ cells----1件: 65 💬
21Dietary Supplement for PKU patients----1件: 240 💬
22EF1aS-ADA lentiviral vector transduced patient CD34+ cells----1件: 65 💬
23ETIMS (EDC-fixed autologous PBMCs coupled with 7 immunodominant myelin peptides in MS patients)1件: Myelin basic protein---1件: 13 💬
24Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector----1件: 65 💬
25Ex-vivo approach concerning 25 patients----2件: 102, 299 💬
26Exelon 4.6 mg/24 h transdermal patch1件: Rivastigmine (Mylan-rivastigmine Patch 10)1件: Rivastigmine 💬1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6 💬
27Exelon 9.5 mg/24 h transdermal patch1件: Rivastigmine (Mylan-rivastigmine Patch 10)1件: Rivastigmine 💬1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6 💬
28Exelon Patch1件: Rivastigmine (Mylan-rivastigmine Patch 10)1件: Rivastigmine 💬1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6 💬
29Exelon Patch (rivastigmine transdermal system)1件: Rivastigmine (Mylan-rivastigmine Patch 10)1件: Rivastigmine 💬1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6 💬
30Exelon path transdermal1件: Rivastigmine (Mylan-rivastigmine Patch 10)1件: Rivastigmine 💬1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6 💬
31Fentanyl transdermal patch1件: Fentanyl (Ran-fentanyl Matrix Patch)1件: Fentanyl 💬1件: OPRM1 💬3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬1件: 46 💬
32Gamma-secretase/Notch signalling pathway inhibitor RO4929097----1件: 74 💬
33Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg1件: Golimumab1件: Golimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 97 💬
34Growth hormone replacement therapy in growth hormone deficient patients only.1件: Somatotropin---1件: 78 💬
35Heparin & Alkalinized Lidocaine Bladder Instillation
(LIDOCAINE PATCH)
2件: Heparin,
Lidocaine (Maximum Strenght Lidocaine plus Menthol Pain Relief Patch)
3件: Lidocaine (LIDOCAINE PATCH),
Adomiparin ,
Lidocaine hydrochloride monohydrate 💬
6件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A,
SERPINC1 💬
4件: Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction 💬1件: 226 💬
36HP-3000 (ropinirole hydrochloride patch)1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
37HP-3000(ropinirole hydrochloride patch)1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
38In-vitro approach concerning 25 patients----2件: 102, 299 💬
39Intervention for incipient patients at low risk of disease progression----1件: 66 💬
40Intervention for patients at high risk of disease progression----1件: 66 💬
41Lidocaine
(LIDOCAINE PATCH)
1件: Lidocaine (Maximum Strenght Lidocaine plus Menthol Pain Relief Patch)2件: Lidocaine (LIDOCAINE PATCH),
Lidocaine hydrochloride monohydrate 💬
5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬12件: 6, 13, 22, 34, 46, 51, 70, 86, 107, 168, 226, 256 💬
42Lidocaine 1% Injectable Solution
(LIDOCAINE PATCH)
1件: Lidocaine (Maximum Strenght Lidocaine plus Menthol Pain Relief Patch)2件: Lidocaine (LIDOCAINE PATCH),
Lidocaine hydrochloride monohydrate 💬
5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 34 💬
43Lidocaine 2% without vessel constrictor
(LIDOCAINE PATCH)
1件: Lidocaine (Maximum Strenght Lidocaine plus Menthol Pain Relief Patch)2件: Lidocaine (LIDOCAINE PATCH),
Lidocaine hydrochloride monohydrate 💬
5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 51 💬
44Lidocaine Hydrochloride, Injectable
(LIDOCAINE PATCH)
1件: Lidocaine (Maximum Strenght Lidocaine plus Menthol Pain Relief Patch)2件: Lidocaine (LIDOCAINE PATCH),
Lidocaine hydrochloride monohydrate 💬
5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 70 💬
45Lidocaine Injection 2%
(LIDOCAINE PATCH)
1件: Lidocaine (Maximum Strenght Lidocaine plus Menthol Pain Relief Patch)2件: Lidocaine (LIDOCAINE PATCH),
Lidocaine hydrochloride monohydrate 💬
5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 168 💬
46Lidocaine patch 5%1件: Lidocaine (Maximum Strenght Lidocaine plus Menthol Pain Relief Patch)2件: Lidocaine (LIDOCAINE PATCH),
Lidocaine hydrochloride monohydrate 💬
5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 13 💬
47Lidocaine Releasing Intravesical System - LiRIS®
(LIDOCAINE PATCH)
1件: Lidocaine (Maximum Strenght Lidocaine plus Menthol Pain Relief Patch)2件: Lidocaine (LIDOCAINE PATCH),
Lidocaine hydrochloride monohydrate 💬
5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 226 💬
48Local Anesthesia (lidocaine hydrochloride)
(LIDOCAINE PATCH)
1件: Lidocaine (Maximum Strenght Lidocaine plus Menthol Pain Relief Patch)2件: Lidocaine (LIDOCAINE PATCH),
Lidocaine hydrochloride monohydrate 💬
5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 6 💬
49Long term follow up in all patients who received SAR422459 in previous study TDU13583----1件: 301 💬
50Loxoprofen sodium hydrogel patch1件: Loxoprofen1件: Loxoprofen 💬2件: PTGS1,
PTGS2 💬
23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 271 💬
51Neupro 2 mg/24 h transdermal patch1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
52Neupro 2mg/24 h transdermal patch1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
53Neupro 2mg/24h transdermal patch1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
54Neupro 4 mg/24 h transdermal patch1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
55Neupro 4mg/24 h transdermal patch1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
56Neupro 4mg/24h transdermal patch1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
57Neupro 4Mg/24Hr Transdermal Patch1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
58Neupro 6 mg/24 h transdermal patch1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
59Neupro 6mg/24 h transdermal patch1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
60Neupro 6mg/24h transdermal patch1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
61Neupro 8 mg/24 h transdermal patch1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
62Neupro 8mg/24h transdermal patch1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
63Nicotine patch1件: Nicotine (Nicoderm Trd 36mg Nicotine/7 Sqcm Patch)1件: Nicotine 💬16件: CHRNA1,
CHRNA10,
CHRNA2,
CHRNA3,
CHRNA4,
CHRNA5,
CHRNA6,
CHRNA7,
CHRNA9,
CHRNB1,
CHRNB2,
CHRNB3,
CHRNB4,
CHRND,
CHRNE,
CHRNG 💬
8件: Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬2件: 6, 84 💬
64Nicotine transdermal patch1件: Nicotine (Nicoderm Trd 36mg Nicotine/7 Sqcm Patch)1件: Nicotine 💬16件: CHRNA1,
CHRNA10,
CHRNA2,
CHRNA3,
CHRNA4,
CHRNA5,
CHRNA6,
CHRNA7,
CHRNA9,
CHRNB1,
CHRNB2,
CHRNB3,
CHRNB4,
CHRND,
CHRNE,
CHRNG 💬
8件: Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬1件: 6 💬
65Observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi4件: Epoprostenol,
Iloprost,
Macitentan,
Selexipag
4件: Epoprostenol ,
Iloprost ,
Selexipag ,
Macitentan 💬
3件: EDNRA,
EDNRB,
PTGIR 💬
10件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Platelet activation, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86 💬
66PAT----1件: 160 💬
67PAT-001, 0.1%----1件: 160 💬
68PAT-001, 0.2%----1件: 160 💬
69Patient Current Care----1件: 46 💬
70Patient treated with DMARD----1件: 46 💬
71Patients will be randomized to receive EHP-101----1件: 51 💬
72Patients' existing non-steroidal anti-inflammatory drug (NSAID) at approved doses----1件: 46 💬
73PD patients H&Y=1.5-2 Medications OFF----1件: 6 💬
74PD patients H&Y=1.5-2 Medications ON----1件: 6 💬
75PD patients H&Y=3 Medications OFF----1件: 6 💬
76PD patients H&Y=3 Medications ON----1件: 6 💬
77PKD Patients----1件: 6 💬
78Rituximab, observational study amon patients with active RA1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
79Rivastigmin Luye Transdermal Patches - 4.6mg/24h----1件: 6 💬
80Rivastigmine Luye Transdermal Patch- 9.5mg/24h1件: Rivastigmine (Mylan-rivastigmine Patch 10)1件: Rivastigmine 💬1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6 💬
81Rivastigmine Patch 9.5 cm21件: Rivastigmine (Mylan-rivastigmine Patch 10)1件: Rivastigmine 💬1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6 💬
82Rivastigmine transdermal patch1件: Rivastigmine (Mylan-rivastigmine Patch 10)1件: Rivastigmine 💬1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬2件: 6, 13 💬
83Rotigotine transdermal patch1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
84Rotigotine transdermal patch 2mg/24h(10cm2)1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
85Rotigotine transdermal patch 4mg/24h (20cm2)1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
86Rotigotine transdermal patch 6mg/24h (30cm2)1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
87Rotigotine transdermal patch 8mg/24h (40cm2)1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
88Routine transdermal oestrogen patch----1件: 78 💬
89The effectiveness of Xeljanz in rheumatoid arthritis patients1件: Tofacitinib1件: Tofacitinib 💬4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46 💬
90TNF-blockers suspension in patients with rheumatoid arthritis----1件: 46 💬
91Top down treatment if patient at high risk----2件: 96, 97 💬
92Transduced patient CD34+ cells----1件: 65 💬
93Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms1件: Lansoprazole1件: Lansoprazole 💬2件: ATP4A,
ATP4B 💬
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98 💬